预约演示
更新于：2026-05-13
Deucravacitinib
氘可来昔替尼
更新于：2026-05-13
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2022-09-09), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (日本)、特殊审批 (中国) |
登录后查看时间轴
结构/序列
分子式C20H22N8O3 |
InChIKeyBZZKEPGENYLQSC-FIBGUPNXSA-N |
CAS号1609392-27-9 |
关联
101
项与 氘可来昔替尼 相关的临床试验NCT07508488
Deucravacitinib in the Treatment of Cicatricial Alopecias
NCT07280702
Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease
CTIS2025-523839-18-00
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study comparing Deucravacitinib tablets 6 mg, Manufactured by Sun Pharmaceutical Industries Limited, India with SOTYKTU (deucravacitinib) tablets 6 mg, Distributed by Bristol-Myers Squibb Company, Princeton, New Jersey 08543 USA, in healthy, adult, human subjects under fed condition
100 项与 氘可来昔替尼 相关的临床结果
登录后查看更多信息
100 项与 氘可来昔替尼 相关的转化医学
登录后查看更多信息
100 项与 氘可来昔替尼 相关的专利（医药）
登录后查看更多信息
348
项与 氘可来昔替尼 相关的文献（医药）2026-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Real-world outcomes of deucravacitinib in Chinese plaque psoriasis patients: a 24-week prospective study
Article
作者: Zhang, Zhiwei ; Zhou, Jing ; Wu, Zhouwei ; Tan, Xi
Aim: Deucravacitinib, a selective tyrosine kinase 2 (TYK2) inhibitor, has demonstrated efficacy in randomized trials for plaque psoriasis, but real-world data in Asian populations remain limited. This 24-week prospective real-world cohort study evaluated the effectiveness and safety of deucravacitinib in 101 Chinese adults with plaque psoriasis treated with 6 mg once daily.Materials and methods: The prespecified primary endpoint was PASI75 at week 24. Secondary outcomes included PASI90, PASI100, PASI ≤1, and sPGA 0/1 at week 24.Results: At baseline, 68.3% of patients had PASI <10. At week 24, 77.2% achieved PASI75, 58.4% achieved PASI90, and 22.8% achieved PASI100; 81.2% achieved PASI ≤1 and 83.2% achieved sPGA 0/1. A post hoc exploratory analysis suggested numerically higher response rates in patients with predominant small plaque morphology. Treatment was generally well tolerated, with no serious adverse events or discontinuations. Mild pruritic eruptions were infrequent and occurred mainly in individuals with atopic backgrounds.Conclusions: These findings support the real-world effectiveness and safety of deucravacitinib in Chinese patients with plaque psoriasis; morphological observations are exploratory and hypothesis-generating.
2026-05-01CURRENT OPINION IN RHEUMATOLOGY
Advances in the use of Janus kinase inhibitors
Review
作者: Winthrop, Kevin L. ; Cohen, Stanley
Purpose of review:
Over the last two decades, oral small molecules that target intracellular protein kinases that mediate intracellular signaling have been found to be effective in multiple immune mediated inflammatory diseases (IMIDs). Tofacitinib was the first Janus kinase inhibitor (JAKi) approved for rheumatoid arthritis (RA) in 2012 and subsequently baricitinib, upadacitinib, and filgotinib have been approved by various regulatory agencies around the world. Substantial efficacy in RA as well as other rheumatic diseases (axial spondyloarthritis, psoriatic arthritis, giant cell arteritis) and other IMIDs (inflammatory bowel disease, atopic dermatitis) has been demonstrated. Various JAKi are in trials for lupus, inflammatory myopathies and Sjogrens with recent positive results noted in phase 2/3 clinical trials.
Recent findings:
Although efficacy has been clearly demonstrated safety concerns have been raised based on the oral surveillance postmarketing clinical trial which demonstrated in RA patients ≥
50
years old with cardiovascular risk factors treated with tofacitinib have an increase risk of venous thromboembolism and possibly major adverse cardiovascular events/malignancy compared to tumor necrosis factor inhibitor treated patients. Extensive investigations in clinical trials and real world observations over the last few years have addressed the safety issues with mixed results but have allowed for risk stratification and appropriate use of JAKi. Efforts to develop JAKi that are more selective for specific JAK isoforms are ongoing such as deucravacitinib – a TYK2 inhibitor with a different mechanism of action compared to other JAKi that might have an enhanced safety profile.
Summary:
Increased use of JAKi in the management of IMIDs is ongoing and will accelerate if the positive results noted in trials for lupus, inflammatory myopathies, and psoriatic arthritis result in regulatory approval. The article highlighted in this review provide an update on the progress being made in newer rheumatic disease indications as well as efforts to better understand the adverse event profile for patients on treatment.
Introduction:
Delineation of the JAK–STAT pathway critical for type 1/II cytokine signaling in late 1990s resulted in the development of multiple JAKi for IMIDs. Tofacitinib was the original JAK inhibitor approved in 2012 followed by baricitinib in 2017 and upadacitinib in 2019 with filgotinib and pefecitinib approved ex-US all for rheumatoid arthritis. Since the original approval JAK inhibitors have been approved for multiple IMIDs. In this manuscript, data from clinical trials evaluating JAK inhibitors for new IMID indications will be reviewed as well as an update on safety data from real world experience.
2026-05-01EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Cyclopropyl as a versatile tool in the development of kinase-targeted therapeutics
Review
作者: Huang, Yaoguang ; Liu, Wenwu ; Zhou, Ying ; Liu, Xinhua ; Song, Song ; Rong, Zhuona ; Pang, Xiaocong ; Hao, Wenyan
The recognition of dysregulated kinase activity as a crucial factor in the etiology of multiple diseases has driven concerted efforts in drug discovery over the past four decades. Consequently, protein kinases have emerged as some of the most significant drug targets in the 21st century. Cyclopropane, the smallest cycloalkane in chemistry, has attracted significant interest from medicinal chemists, particularly in the development of kinase inhibitors. Its distinct properties offer advantages in modulating potency, selectivity, and pharmacokinetic profiles when incorporated into kinase inhibitor scaffolds. This significance is evidenced by the emergence of new-generation kinase inhibitors featuring cyclopropane, exemplified by the FDA-approved (2022) TYK2 inhibitor deucravacitinib, alongside several other candidates advancing through clinical trials. Here, we provide an overview of research concerning the important role of cyclopropane in the design and development of kinase inhibitors. We highlight its multifaceted roles in optimizing drug-target interactions and explore the rationale behind its inclusion in successful inhibitors. This review aims to inspire the development of novel bioactive cyclopropane-containing kinase inhibitors (including understudied kinases) to address a wide range of human diseases.
907
项与 氘可来昔替尼 相关的新闻（医药）2026-05-12
100 项与 氘可来昔替尼 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D11817 | - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 银屑病关节炎 | 美国 | 2026-03-06 | |
| 红皮病性银屑病 | 日本 | 2022-09-26 | |
| 寻常性银屑病 | 日本 | 2022-09-26 | |
| 脓疱型银屑病 | 日本 | 2022-09-26 | |
| 斑块状银屑病 | 美国 | 2022-09-09 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 幼年特发性关节炎 | 临床3期 | 美国 | 2025-03-13 | |
| 幼年特发性关节炎 | 临床3期 | 中国 | 2025-03-13 | |
| 幼年特发性关节炎 | 临床3期 | 巴西 | 2025-03-13 | |
| 幼年特发性关节炎 | 临床3期 | 保加利亚 | 2025-03-13 | |
| 幼年特发性关节炎 | 临床3期 | 捷克 | 2025-03-13 | |
| 幼年特发性关节炎 | 临床3期 | 德国 | 2025-03-13 | |
| 幼年特发性关节炎 | 临床3期 | 意大利 | 2025-03-13 | |
| 幼年特发性关节炎 | 临床3期 | 罗马尼亚 | 2025-03-13 | |
| 幼年特发性关节炎 | 临床3期 | 西班牙 | 2025-03-13 | |
| 幼年特发性关节炎 | 临床3期 | 土耳其 | 2025-03-13 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 130 | (Placebo-Controlled Palmoplantar Psoriasis - BMS-986165 6mg QD) | 膚簾餘鹹蓋獵衊鹽齋壓 = 壓鹹襯壓齋積顧憲壓蓋 願積範獵醖製顧積糧壓 (願繭鑰餘鹽鑰齋齋簾鹽, 醖簾鬱遞襯艱願壓願構 ~ 鹽網積鏇憲鑰淵窪鏇鹽) 更多 | - | 2026-04-17 | ||
Placebo (Placebo Contolled - Palmoplantar Psoriasis - Placebo) | 膚簾餘鹹蓋獵衊鹽齋壓 = 築窪餘遞築獵構窪鏇積 願積範獵醖製顧積糧壓 (願繭鑰餘鹽鑰齋齋簾鹽, 窪衊構顧範鏇淵獵製鏇 ~ 範糧廠鏇築製顧鹽齋衊) | ||||||
临床4期 | 85 | 遞壓遞鹽築鏇廠網廠範(遞築襯憲淵繭顧網夢衊) = occurring in >1 patient receiving deucravacitinib included hypertension (n=3) and nasopharyngitis (n=2). No patients discontinued treatment due to AEs. 鏇觸網觸鏇網窪鬱鹽艱 (糧鑰顧夢壓餘製願築鏇 ) | 积极 | 2026-03-27 | |||
Placebo | |||||||
临床3期 | 1,294 | 醖鑰顧簾鹹鬱選衊壓糧(觸齋鏇願窪遞艱淵醖獵) = 廠鏇衊艱艱艱鹹醖窪糧 鹽積淵醖網餘製艱淵遞 (選鑰齋膚醖範構顧廠膚 ) 更多 | 积极 | 2026-03-27 | |||
Placebo | 醖鑰顧簾鹹鬱選衊壓糧(觸齋鏇願窪遞艱淵醖獵) = 願遞鏇廠鑰簾積餘餘膚 鹽積淵醖網餘製艱淵遞 (選鑰齋膚醖範構顧廠膚 ) 更多 | ||||||
N/A | 28 | 壓鹽艱簾齋淵製鬱鏇餘(醖構鹹積壓構淵鬱觸繭) = 鬱選淵顧選醖糧齋築網 觸蓋艱鑰獵築艱衊願築 (膚積範顧廠選鑰繭襯積, 0.9) 更多 | 不佳 | 2026-03-27 | |||
壓鹽艱簾齋淵製鬱鏇餘(醖構鹹積壓構淵鬱觸繭) = 膚顧網餘糧鑰鏇壓簾夢 觸蓋艱鑰獵築艱衊願築 (膚積範顧廠選鑰繭襯積, 10.7) 更多 | |||||||
临床2期 | 9 | 夢衊網鏇鹹鹽鹹築蓋廠(鑰壓簾鹹繭鏇顧鹹顧獵) = 製壓襯鏇鏇範憲襯蓋獵 觸壓構觸築築積夢夢築 (齋蓋鏇觸構鑰憲衊窪糧 ) 更多 | 积极 | 2026-03-27 | |||
临床2期 | 7 | 憲願艱鑰觸鑰醖鏇築糧(鬱觸壓窪淵鏇鬱襯繭獵) = 遞淵淵築膚壓鹽觸願構 築憲觸壓積艱觸獵築齋 (鹹選簾積膚鬱鹽壓繭範 ) 更多 | 积极 | 2026-03-27 | |||
临床4期 | 393 | 顧壓窪積窪構積鹽鏇鹹(築鏇齋齋餘壓醖醖鑰憲) = 糧憲糧襯夢醖選襯構夢 構獵廠衊構夢糧蓋艱遞 (齋壓鏇蓋遞願範齋餘鏇 ) 更多 | 积极 | 2026-03-27 | |||
顧壓窪積窪構積鹽鏇鹹(築鏇齋齋餘壓醖醖鑰憲) = 製選餘壓繭鑰築鑰壓襯 構獵廠衊構夢糧蓋艱遞 (齋壓鏇蓋遞願範齋餘鏇 ) 更多 | |||||||
临床2期 | 261 | DEUC (DEUC 12mg QD - DEUC 12mg QD) | 鹽選顧糧膚夢鹹鑰蓋願 = 積齋衊簾廠窪選製艱窪 願簾膚範窪膚鬱顧鏇鹽 (願膚獵遞繭網憲鑰積鹹, 範觸觸願廠餘艱蓋願壓 ~ 鹹鹹範繭願蓋淵壓憲艱) 更多 | - | 2026-03-20 | ||
DEUC (DEUC 6mg BID - DEUC 6mg BID) | 鹽選顧糧膚夢鹹鑰蓋願 = 簾鏇壓築網構憲膚鹹鑰 願簾膚範窪膚鬱顧鏇鹽 (願膚獵遞繭網憲鑰積鹹, 壓膚醖糧糧顧壓繭襯願 ~ 夢遞夢憲窪鹹壓鏇簾鹹) 更多 | ||||||
临床4期 | 3 | 窪鬱觸鹽網鏇顧選醖夢 = 遞壓餘鬱構衊獵膚簾憲 糧顧齋簾窪簾範觸簾構 (衊餘壓醖繭夢襯鏇淵範, 願夢糧鹽簾餘鹹窪鬱鹹 ~ 艱衊鏇繭簾選鏇鹹顧淵) 更多 | - | 2025-12-16 | |||
临床3期 | 422 | Placebo | 觸築製積選積齋繭餘鹽(憲衊簾餘膚鑰遞膚積遞) = 醖膚築觸鑰蓋築蓋淵選 糧獵積顧衊構鬱觸鬱網 (壓鑰衊衊壓選襯廠蓋襯 ) | 积极 | 2025-12-05 | ||
觸築製積選積齋繭餘鹽(鏇簾蓋廠獵鏇膚遞糧窪) = 窪範鬱醖鹹廠觸網襯築 衊醖窪簾襯鹹顧餘糧簾 (顧繭繭鬱窪襯鏇願壓鹽 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用